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Abstract
Background: Herein, we demonstrated the use of a newly generated anti FAT1 antibody (clone mAB198.3) for
intracellular delivery of anionic gold NPs, to form active targeting Au nanoparticles with high payload characteristics.
Methods: In vitro characterizations were determined by DLS, confocal microscopy, TEM, western blot, MALDI-TOF
MS/MS analysis, MTT, ICP-MS and flow cytometry analysis. In vivo targeting efficacy was investigated by in vivo
bio-imaging study and ICP-MS.
Results: The specificity of the FAT1 recognition in colon cancer was confirmed by pre-adsorbing mAb198.3, adsorption
dramatically abolished the antibody reactivity on colon cancer, thus confirming the binding specificity. The DLS size
distribution profile of the AuCOOH, AuCOOH(Cy5)_ mAb198.3, AuCOOH(Cy5)_isotype has showed that the modified
gold nanoparticles are well dispersed in water, PBS buffer and cell culture medium with 10 % FBS. By TEM measurement,
the size of Au nanoparticles with spherical morphology is about 10–20 nm. AuCOOH_198.3 NPs were stable in an acidic
environment, as well as in PBS buffer, cell culture media and media with 10 % serum. MTT results revealed that Au
nanoparticles have well biocompatibility. TEM results indicated that conjugation of mAb198.3 on Au nanoparticles can
be an effective delivery vehicle for negatively charged gold nanoparticles and increased its intracellular transport. It was
also demonstrated by confocal microscopy that AuCOOH(Cy5)_mAb198.3 could attach to the cell membrane in very
short time, then gradually delivered into cells. After 4 h incubation, almost all AuCOOH(Cy5)_mAb198.3 have been
uptaken into or surrounding the cytoplasm and nucleus. In vivo results showed that only about 20 % of AuCOOH
accumulated in tumor site due to EPR effect, while nearly 90 % of AuCOOH_mAb198.3 was found in tumor, providing
sufficient evidence for receptor-specific targeting by mAb198.3.
Conclusion: According to in vitro and in vivo research results, the intracellular uptake of negatively charged AuCOOH_
mAB198.3 particles is enhanced to a greater extent. Thus, AuCOOH_mAb198.3 holds significant potential to improve the
treatment of cancer.
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Nanoscaled drug carriers have been used widely for drug
delivery such as liposomes [1, 2], microspheres [3–6],
polymeric shells [7], micelles, niosomes, nanoparticles
[8], dendrimers and nanofibers [9]. The drug was loaded
on or into these nanoscaled materials by several different
techniques, such as encapsulation, surface loading, hydro-
gen bonding, and other types of interactions. However,
the drug loading efficiency of the current nanoparticle
drug delivery systems based on polymers are still low [10].
Therefore, improving loading efficiency is a critical factor
in the design of drug delivery systems. Au nanoparticles
can offer significant advantages over these delivery mecha-
nisms in terms of high stability [11], high specificity [12],
high drug carrying capacity [13], ability for controlled re-
lease [14] and the capability to transport both hydrophilic
and hydrophobic molecules.
The presence of phospholipids on the mammalian cell
membrane imparts a net negative charge [15], restricting
anionic entities to bind and subsequent transport into
the cell. For example, Xia et al. have demonstrated that
the membrane affinity constant as well as the rate of in-
ternalization of cationic NPs is significantly higher than
that of anionic NPs in human cancer cells [16]. Despite
high uptake efficiency, cationic NPs tend to be toxic [17]
and can elicit immunotoxic [18] and genotoxic [19]
responses in a variety of cells. In contrast, anionic nano-
particles are nontoxic [20] and minimize the protein
adsorption on their surfaces [21], thereby improving the
pharmacokinetic profile [22]. Using an in vitro tumor
model, we have also shown that the anionic gold NPs can
diffuse faster and would be a better candidate to deliver
drugs deep inside the tissues [23]. Therefore, strategies to
enhance the intracellular uptake of negatively charged
NPs can aid the drug penetration into the tumor core,
circumventing the possible cytotoxicity issues.
FAT1 is a surface exposed protein. It belongs to the
human FAT gene family, a subclass of the cadherin super-
family composed of four giant proteins (from FAT1 to
FAT4) of 500–600 kDa sharing structural similarities from
invertebrates to mammals. Human FAT1 is a typeI trans-
membrane protein composed of 34 cadherin repeats, five
EGF-like repeats, a laminin A-G domain in the extracellu-
lar region and a cytoplasmic tail that is quite distinct from
classical cadherins [24, 25]. The protein was recently iden-
tified as a novel colorectal cancer (CRC)-associated
marker (Grifantini et. al., submitted manuscript) by an
immune-histochemical screening of a collection of anti-
bodies towards membrane-associated and secreted pro-
teins so far marginally characterized in the scientific
literature [24]. One particular mAb was generated in our
lab named as mAb198.3. MAb198.3 recognizes the FAT1
protein in CRC, in which is gives a predominant mem-
branous staining (Grifantini et. al., submitted manuscript).
Moreover, mAb198.3 is rapidly internalized when it binds
to FAT1-expressing colon cell lines (Grifantini et. al.,
submitted manuscript). Based on these findings, this novel
marker and specific mAb could offer new opportunities
for negative gold nanoparticles intracellular delivery,
cancer diagnosis and treatment [26].
In this study, by using an independent collection of
clinical samples, we further confirmed that mAb198.3
recognizes FAT1 in 79 % colon adenocarcinomas, while it
is negative or marginal expressed in most normal human
tissues when tested on 24 different healthy human tissues
analyzed by immunohistochemistry (IHC). Moreover, we
investigated the internalization properties of mAb198.3
bound to nanoparticles. MAb198.3 was designed to conju-
gate on Au nanoparticles backbone to form active targeting
Au nanoparticles with high payload characteristics. Herein,
we demonstrated the use of mAb198.3 for intracellular
delivery of anionic gold NPs (Fig. 1). Results showed that
conjugation of mAb198.3 on anionic gold nanoparticles
could effectively deliver particles into tumor cells or tissues
but rarely into normal cells. This active targeted delivery
system with high payload capacity could be considered as a
promising targeting anti-tumor drug delivery system.
Experimental section
Materials
All reagents were purchased from Sigma Aldrich without
purification, unless otherwise mentioned. Dichloromethane
(DCM) as a solvent for chemical synthesis was dried to re-
move excess water. NMR spectra were detected by a Bruker
AVANCE 400 machine. TEM images were acquired on a
JEOL 7C at 80 keV. Dynamic light scattering (DLS) data
were measured with a Malvern Zetasizer Nano ZS.
Methods
Cloning-expression-purification of recombinant FAT1
The FAT1 domain spanning from amino acid 723 to amino
acid 1352 of the protein was selected for cloning and ex-
pression in E.coli. For cloning, cDNA pools were generated
by reverse transcription from total RNAs (Euroclone) of
human tissues (bone marrow, fetal brain, placenta and
testis) and pooled. The corresponding cDNA fragment was
amplified using specific primers (selected using Primer 3
Software, Premier Biosoft International) so as to fuse a 10
histidine tag sequence (MGSDKIHHHHHHHHHHGV) at
the 5′ end, annealed to in-house-developed vector (p2N)
derivative of vector pSP73 (Promega) adapted for the T4
ligation independent cloning method [27]and used to trans-
form E.coli NovaBlue cell recipient strain. E. coli transfor-
mants were plated onto selective LB plates containing
100 μg/ml ampicillin (LB Amp), and positive E.coli clones
were identified by restriction enzyme analysis of purified
plasmid followed by DNA sequence analysis. For expres-
sion, the p2N-FAT1 plasmid was used to transform BL21-
(DE3) E.coli cells. Recombinant FAT1 (rFAT1) was purified
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from the inclusion bodies. Briefly, E.coli BL21-(DE3) cells
harboring the p2N-FAT1 were inoculated in 50 ml of
ZYP-5052 growth medium and grown at 37 °C for 24 h.
Afterwards, bacteria were harvested by centrifugation and
lysed into 10 ml of B-Per Reagent (Pierce) containing
1 mMMgCl2, 10 units/ml of DNAse I (Sigma), and 1 mg/ml
Lysozyme (Sigma). After 30 min at room temperature under
gentle shaking, the insoluble inclusion bodies were collected
by centrifugation at 30.000 × g for 40 min at 4 °C. To
solubilize inclusion bodies, the pellet was resuspended in
10 ml of 6 M guanidine hydrochloride, 1 mM Tris(2-car-
boxyethyl)-phosphine hydrochloride (TCEP) (Pierce), and
40 mM Tris–HCl pH 8. After clarification by centrifugation
at 30.000 g for 30 min, the supernatant was loaded on
0.5 ml columns of Ni-activated Chelating Sepharose Fast
Flow resin (GE-Healthcare). After washing the resin with
10 column volumes of 6 M urea, 60 mM imidazole, 0.5 M
NaCl, 1 mM TCEP, and 50 mM Tris–HCl pH 8, recombin-
ant proteins were eluted with the same buffer containing
500 mM imidazole. The purity of rFAT1 was analyzed
by SDS-Page and its concentration was determined by
Bradford assay using the BIORAD reagent (BIORAD) with
a bovine serum albumin standard according to the manu-
facturer’s recommendations. Moreover, the identity of the
protein was verified by MALDI-TOF MS/MS analysis as
described [24].
Production of hybridomas and purification of mAbs
Hybridoma cells were generated according to our standard
protocol [28]. BALB/c mice (8 weeks old, female) were
immunized with 20 μg of rFAT1, mixing with complete
Freund’s adjuvant by subcutaneous (s.c.) injection and im-
munized every 4 weeks using 20 μg of rFAT1. 10 days after
final immunization, the concentration of anti-FAT1
antibodies in sera was monitored by indirect ELISA.
Splenocytes and SP2/0 myeloma cells were mixed in
50 % PEG solution (Mw4000). The positive hybridomas
were selected and subcloned.
BALB/c mice were inoculated with 1 × 106 hybrid-
oma cells by i.p. injection and the ascitic fluid was col-
lected after 7–14 days. The fraction of mAbs in ascites
was precipitated with 50 % ammonium sulphate and
futher purified by ProteinG-Sepharose CL-4B chroma-
tography. Obtained IgG fractions were dialysis in PBS
and stored at −70 °C.
Cell culture
Colo 205 cells (Human Colon Carcinoma) and HeLa
cells were cultured in RPMI 1640 and DMEM, respec-
tively, supplemented with 10 % fetal bovine serum and
1 % antibiotics. The cells were maintained at 37 °C
incubator with 5 % CO2.
Cell transfection
For transfection experiments, the FAT1 encoding plasmid
was generated by PCR amplifying the full length coding
region specific primer pairs (acid 723 to amino acid 1352,
Forward: 5′-gaattcggtattcaggtaaaggaaaacc-3′; Reverse: 5′-
ctcgagctaggacggtttgggcttggag-3′), and the PCR products
were cloned into plasmid pcDNA3 (Invitrogen) and
Fig. 1 Intracellular negative gold nanoparticles delivery. a Configurations of Au nanoparticles. b Schematic of FAT1 mediated endocytosis and
drug release of AuCOOH_mAb198.3
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sequence-verified. HeLa cells (400,000 per well, in 6-well
plates) were transiently transfected with 4 micrograms of
the resulting plasmids and with the empty vector as nega-
tive control (mock) using the Lipofectamine-2000 transfec-
tion reagent (Invitrogen). Cells were collected for Western
blot analysis 24 h after transfection and analysed for FAT1
expression by Western blot.
Western blot
Sub-confluent cell mono-layers were detached with
PBS-0.5 mM EDTA and lysed by several freeze-thaw
passages in PBS-1 % Triton. Total protein extracts
were loaded onto a SDS-Page (2x105 cells/lane) and
expression of target proteins was assessed by Western
blot analysis using the FAT1 specific mAb198.3. Western
blot was performed by separation of the protein extracts on
pre-cast SDS-PAGE gradient gels (NuPage 4-12 % Bis-Tris
gel, Invitrogen) under reducing conditions, followed by
electro-transfer to nitrocellulose membranes (Invitrogen)
according to the manufacturer’s recommendations. The
membranes were blocked in blocking buffer composed of
1x PBS-0.1 % Tween 20 (PBST) added with 10 % dry milk,
for 1 h at room temperature, incubated with the antibody
diluted 1:2500 in blocking buffer containing 1 % dry milk
and washed in PBST-1 %. The secondary HRP-conjugated
antibody (goat anti-mouse immunoglobulin/HRP, Perkin
Elmer) was diluted 1:5000 in blocking buffer, and chemilu-
minescence detection was carried out using a Chemidoc-IT
UVP CCD camera (UVP) and the Western Lightning™
Cheminulescence Reagent Plus (Perkin Elmer), according
to the manufacturer’s protocol. Where indicated, antibodies
used for Western blot were pre-adsorbed at 4 °C on
membranes saturated with their respective recombin-
ant proteins.
Confocal microscopy analysis of FAT1 expression
For confocal microscopy analysis of FAT1 expression,
cells were seeded on cover slips. After 48 h incubation,
cells were washed by PBS and fixed with 3 % formalde-
hyde solution for 20 min. After washing by PBS for sev-
eral times, cells were permeabilized with 0.01 % BriJ96®
(Fluka) and incubated with antibodies (1:200) overnight at
4 °C. Cells were then stained with Alexafluor 488-labeled
goat anti-mouse antibodies (Molecular Probes). DAPI
(Molecular Probes) was used to stain nuclei. The cells
were mounted with glycerol plastine and observed using
confocal microscope (LeicaSP5).
IHC staining
Tissue arrays of 24 normal human tissues (FDA808c)
and colon carcinoma tissues (BC05118a) were purchased
from US Biomax Inc. Tissue arrays were treated by
dimethyl benzene and rehydrated using alcohols with
different ratios. Methanol containing 3 % H2O2 was used
for blocking endogenous peroxidase activity for 10 min,
while nonspecific binding was blocked by PBS contain-
ing 10 % normal goat serum for 30 min. The slices were
incubated with mAb198.3 (0.2 mg/L) for 1 h. Normal
mouse IgG was collected as negative control. After washing
by PBS for 3 times, the slices were dipped into biotin-
conjugated goat anti-mouse IgG (Promega, Madison, USA)
for 1 h at room temperature, incubated for another hour
with streptavidin-HRP complex (Promega, Madison, USA).
Then antibody complexes were stained by DAB chromo-
gen. Tissue arrays were counterstained with Mayer’s
hematoxylin for 30 s, followed by dehydrated through
gradient ethanol, cleared in dimethyl benzene, mounted,
and examined using light microscopy.
Preparation of poly(ethylene glycol) 2-mercaptoethyl ether
acetic acid (COOH-PEG-SH) capped gold nanoparticles
(AuCOOH)
2 nm gold NPs was synthesized following Brust- Schiffrin
method [29] with some modification. An aqueous solution
of hydrogen tetrachloroaurate (1 g, 250 ml) was mixed with
a solution of tetraoctylammonium bromide in toluene
(2.1 g, 500 ml). The two-phase mixture was vigorously
stirred until all the tetrachloroaurate was transferred into
the organic layer and C5SH (0.337 ml) was then added to
the organic phase. A freshly prepared aqueous solution of
sodium borohydride (2 g, use small amount of water to
dissolve) was quickly added with vigorous stirring. After
further stirring overnight the organic phase was separated,
evaporated with rotary evaporator and mixed with 400 ml
ethanol to remove excess thiol. The mixture was kept at
−18。C and the dark brown precipitate was filtered off and
washed with ethanol many times. The mole ratio of
HAuCl4: TOAB: C5SH: NaBH4 = 1:1.5:1.2: 20.
COOH-PEG-SH capped gold nanoparticles (AuCOOH)
were prepared from pentane thiol-capped gold NPs (~2 nm
core) via a place exchange reaction. Briefly, 20 mg of
pentane thiol-capped 2 nm gold NPs prepared from Brust-
Schiffrin method [30] and 80 mg of COOH-PEG-SH were
weighed in two separate vials and 5 ml dry DCMwas added
to each of the vials. Under nitrogen atmosphere, COOH-
PEG-SH solution was added dropwise to the gold NPs solu-
tion and stirred for 2 days. The black precipitation of
AuCOOH was further washed with Hexane/DCM twice to
remove free ligands, dried under reduced pressure and
solubilized in distilled water. After 2 days of dialysis, the
NPs were lyophilized and redissolved in MilliQ water.
Preparation of Cy5 labeled AuCOOH (AuCOOH_Cy5)
Cy5 as a fluorescence indicator was chosen to simulate
antitumor drug and labeled in AuCOOH. Cy5 NHS
ester was first reacted with cysteamine(SH-C2H4-NH2)
to obtain SH-C2H4-NH-CO-Cy5. And SH-C2H4-NH-
CO-Cy5 capped gold nanoparticles (AuCOOH_Cy5)
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were prepared via a place exchange reaction [31].
Briefly, 15 mg Cy5 NHS ester dissolved in 200 μL
DMSO was dropwised added in cysteamine solution
(1.89 mg, 3 mL 0.1 M PBS with pH 8.3–8.5) and stirred
for 24 h at room temperature under dark. After reac-
tion, the product SH-C2H4-NH-CO-Cy5 was lyophi-
lized and redissolved in small amount of DMSO and
then added to dichloromethane (DCM) for future use.
To obtain AuCOOH_Cy5, 6 mg of SH-C2H4-NH-CO-
Cy5, 34 mg of COOH-PEG-SH and 10 mg of pentane
thiol-capped 2 nm gold NPs were weighed in three
separate vials and 2 mL dry DCM was added to each of
the vials. Under nitrogen atmosphere, COOH-PEG-SH
solution and SH-C2H4-NH-CO-Cy5 solution were added
dropwise to the gold NPs solution and stirred for 2 days.
The dark blue product of AuCOOH_Cy5 was further
washed with Hexane/DCM twice to remove free ligands,
dried under reduced pressure and solubilized in distilled
water. After 2 days of dialysis, the NPs were lyophilized
and redissolved in MilliQ water.
Preparation of mAb198.3 and isotype decorated
AuCOOH_Cy5 (AuCOOH(Cy5)_ mAb198.3)
Attachment of mAb198.3 to the AuCOOH_Cy5 was per-
formed using standard N-hydroxysuccinimide/1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (NHS/EDC) coupling
chemistry. Reaction raw molar ratio was as follow,
AuCOOH_Cy5: EDC: NHS: mAb198.3 (1:10:10:5). Briefly,
the carboxy groups on the particle surface are first activated
by reaction with EDC hydrochloride and NHS in 0.1 M
MES buffer (pH 5) for 1 h. Then mAb198.3 attachment
was performed by adding the concentrated activated nano-
particles to a dilute PBS solution containing mAb198.3 at
pH 7.4. The solution was mixed well and transferred
into an Eppendorf tube and shaken gently overnight at
4 °C under dark. After reaction, free antibody and
AuCOOH(Cy5)_mAb198.3 was separated by fast pro-
tein liquid chromatography (FPLC) to remove free anti-
body, NHS and EDC. The mobile phase was MilliQ water
at a flow rate of 5 mL/min. The final molar ratio of
AuCOOH_Cy5: mAb198 in AuCOOH(Cy5)_mAb198.3
was 1:4.
Attachment of isotype control to the AuCOOH_Cy5 was
performed using the same protocol as AuCOOH(Cy5)_
mAb198.3 preparation by changing mAb198.3 to isotype
control.
Characterization of Au nanoparticles
AuCOOH, AuCOOH_Cy5, AuCOOH(Cy5)_ mAb198.3
and AuCOOH(Cy5)_ isotype were analyzed by dynamic
light scattering, NMR and TEM. Dynamic light scatter-
ing was performed with a Malvern Zetasizer Nano ZS to
determine particles size and potential. Transmission
electron microscopy was done to intuitive study the
dispersibility and uniformity of particle on a JEOL 7C
device at 80 kV. Samples were prepared by dilution of the
nanoparticles in water, placement of a drop (2-3 μL) on a
copper grid carrying a 20 nm thick carbon film (CF-300-
Cu, Electron Microscopy Sciences), and drying for 1 h.
Evaluation of AuNP cytotoxicity on cell viability and
proliferation
Colo 205 cells were seeded in a 96-well plate at a density
~15,000 cells/well 24 h prior to the experiment. Next
day, the old media was replaced by different concentra-
tions of AuCOOH in serum containing media, and the
cells were further incubated for 24 h at 37 °C in a hu-
midified atmosphere of 5 % CO2. The cells were washed
with PBS three times and 10 % alamar blue in serum
containing media was added to each well and further
incubated at 37 °C for 4 h. The cell viability was then
determined by measuring the fluorescence intensity at
590 nm using a SpectraMax M5 microplate spectropho-
tometer. Viability (%) of NP-treated cells was calculated
taking untreated cells as 100 % viable. Each experiment
was done in triplicate.
Flow cytometry assay
Reaction of the mAb198.3_Cy5, isotype antibody_Cy5,
AuCOOH(Cy5)_ mAb198.3 and AuCOOH(Cy5)_ isotype
with Colo205 cells was analyzed using flow cytometry.
Colo 205 cells were harvested and incubated with free
mAb198.3_Cy5, isotype antibody_Cy5, AuCOOH(Cy5)_
mAb198.3 and AuCOOH(Cy5)_ isotype (20nM) for
30 min at 4 °C. After incubation, cells were washed for
three times and resuspended in PBS. Samples were ana-
lyzed using a FACSCalibur flow cytometer and CellQuest™
Pro software (BD Bioscience, San Jose, CA). Each experi-
ment was done in triplicate.
Cell TEM analysis
It is important to know the fate of the nanoparticles
after the treatment. Do the particles internalized by cells
due to mAb198.3 on the particle surface or do the parti-
cles remain bound to the cell membrane? To address
these issues transmission electron microscopy study fol-
lowing standard protocol was performed. Colo 205 cells
were first treated with AuCOOH, AuCOOH(Cy5)_
mAb198.3 and AuCOOH(Cy5)_ isotype for 4 h, separ-
ately. After the incubation, cells were centrifuged gently
at 1000 rpm for 5 min. The resultant cell pellets were then
washed with PBS, and fixed in 2.5 % (v/v) glutaraldehyde
in 0.1 M phosphate buffer, pH 7.2. All samples were then
washed with PBS, pH 7.2, followed by a 1 h postfix in
phosphate-buffered 1 % Osmium tetroxide (OsO4). After
washing in distilled water, the cells were stained with 2 %
uranyl acetate for 30 min at 60 °C. After washed for
another three times, cells were dehydrated in progressively
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higher concentrations of ethanol and 100 % propylene
oxide, and embedded in resin. Cells were cut into thin
pieces on a Reichert Ultracut E ultramicrotome, placed on
200 mesh copper grids, and stained with lead citrate.
Micrographs were taken on a JEOL 7C operating at 80 KV.
Antibody internalization
To demonstrate mAb198.3 mediated cell-selective intracel-
lular delivery of the AuCOOH, cultured cells (5 × 105/
sample) were treated with the AuCOOH(Cy5)_ mAb198.3
and AuCOOH(Cy5)_ isotype for 12 h at 37 °C. Cells
were then washed twice with PBS and fixed with 4 %
triformol solution. Then the cells were stained with
1 μg/ml 4′–6-diamidino-2-phenylindole (DAPI, Invi-
trogen) for 8 min to label nuclei and washed with
PBS for three times to remove free dye. Lastly, cell sus-
pensions were added onto slide and examined using a laser
scanning confocal microscope (Olympus, Fluo ViewTM
1000) at 400 ×magnification.
Animal model
All animal studies were conducted under a protocol
approved by National Institute of Biological Science and
Animal Care Research Advisory Committee of Fourth
Military Medical University. All experiments involving mice
conducted following the guidelines of the Animal Research
Ethics Board of Fourth Military Medical University.
Six-week-old BALB/c athymic nude mice were purchased
from Peking University Health Science Center and tumors
were established by subcutaneously injecting Colo-205
cells of 0.10 mL volume containing 5 × 107 cells/mL media
into the right flank of the mice. The tumor sizes were
monitored every other day and the animals were subjected
to in vivo experiments when the diameter of the tumors
reached 6 ~ 8 mm (typically 3–4 weeks after inoculation).
In vivo bio-imaging study
For in vivo bio-imaging, xenograft tumor mice received
a tail intravenous injection of 2 μmol/L AuCOOH(Cy5)_
mAb198.3, AuCOOH(Cy5)_ isotype solution prepared
in PBS (0.25 mL) and injection concentration of
mAb198.3_Cy5, isotype antibody_Cy5 was 10 μmol/L
(0.25 mL) due to conjugation ratio between Au and
mAb was 1 to 5. The animals were fully anesthetized
by inhalation of a mixture of oxygen with 5 % isoflur-
ane 10–15 min 24 h post-injection. The in vivo bio-
images were acquired using an in vivo fluorescence
imaging system (Cambridge Research & Instrumenta-
tion, Inc., Maestro EX) with Ex = 640 nm.
Tissues were harvested from the mice after in vivo
bio-imaging studies to quantitative analyze nonspecific
accumulation of Cy5 in other organs besides tumor. The
mice were sacrificed by cervical dislocation. Heart, liver,
spleen, lung, kidneys and tumor, along with peripheral
blood in the chest were collected. Organs were washed
by PBS buffer twice and images were also acquired using
the fluorescence imaging system with Ex = 640 nm.
ICP- MS measurements
Inductively coupled plasma mass spectrometry (ICP- MS)
could detect element type and concentration in the sam-
ples. Quantification of gold nanoparticle uptake by cells is
best performed by this technique that has high specificity
and low limits of detection. ICP- MS has excellent limits of
detection (18 parts per trillion for gold) and can be applied
to quantify the cellular uptake by digesting the cells with
strong acid. The amounts of Au uptake were measured on
a Perkin-Elmer Elan 6100 mass spectrometer. Each sample
was measured in triplicate. Colo-205 cells were seeded in
24 well plates at 30,000 cells in 0.5 mL medium 24 h prior
to the experiment. Next day, the cells were washed with
PBS and incubated with AuCOOH, AuCOOH_isotype and
AuCOOH_mAb198.3 NPs (150nM Gold nanoparticles) for
6 h cells were washed three times with PBS and lysed. Cell
lysate was digested with 0.5 mL aqua regia for 4 h. After
digestion, each sample was diluted into 10 mL de-ionized
water, and subjected to ICP-MS analysis. Au uptake in vivo
by tumor was also investigated by ICP-MS following the
same method.
Results and discussion
Generation and characterization of mAbs against FAT1
Our approach to discover novel potential markers and
therapeutic targets is based on IHC screenings of cancer
tissues using large collections of mouse polyclonal and
monoclonal antibodies towards secreted or membrane-
associated poorly known human proteins [24]. An IHC
screening of Tissue microarrays (TMAs) carrying clinical
samples from each of the five major human cancers
(breast, colon, lung, ovary and prostate, duplicated can-
cer and matched normal samples from 5 patients per
each cancer) led to the identification of FAT1 as novel
CRC associated protein.
In particular a murine mAb against a rFAT1 domain,
generated in our laboratories, named as mAb198.3,
emerged from the screening of hybridoma clones secreting
mAbs against human FAT1 region from amino acid 723 to
amino acid 1352 (domain 723–1352). The isotype of
mAb198.3 was IgG1 (κ). The hybridoma was selected by
ELISA screening on the rFAT1 protein. The mAb was
produced as ascites and purified using affinity purification
by ProteinG-Sepharose CL-4B [28]. MAb198.3 specificity
was further confirmed by analyzing its ability to recognize
FAT1 domain 723–1352 expressed in HeLa cells trans-
fected with FAT1-encoding plasmid (Fig. 2a). MAb198.3
could be applied in IHC, confocal microscopy and flow
cytometry on FAT1-transfected cells (data not shown).
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Expression profiles of FAT1 human colon carcinoma
tissues and normal colon tissues detected by mAb198.3
The ability of the mAb198.3 to recognize CRC in IHC
was demonstrated by Externautics (Grifantini et al.,
submitted manuscript). In this study, the expression of
FAT1 was further verified in a new cohort of 43 pa-
tients affected by colon. In this experiment, all of the
negative controls showed no specific positive reaction.
High level expression of FAT1 was detected in 34 cases
(79 %) of colon cancer tissues while there was no FAT1
expression in normal colon tissues (Fig. 2b). As shown
in Fig. 2c-e, specifically recognized CRC showing a
clear membranous staining that extended in part to the
cell cytoplasm, with negligible staining in correspon-
ding normal samples.
The specificity of the FAT1 recognition in colon can-
cer was further confirmed by pre-adsorbing mAb198.3
on nitrocellulose membrane coated with rFAT1 Domain
and re-testing the antibody on colon cancer tissues.
After adsorption, the antibody totally lost the ability to
recognize FAT1 in Western blot analysis of total extracts
of FAT1-transfected cells (not shown). Furthermore,
mAb198.3 adsorption dramatically abolished the anti-
body reactivity on colon cancer, thus confirming the
binding specificity (Fig. 2f-i).
Reaction of mAb198.3 with native FAT1
In previous studies we found that FAT1 is expressed and
surface exposed in a panel of colon cancer cell lines
(Grifantini et al., submitted manuscript). Among the
FAT1-positive cell lines, the colon cell line Colo205 was
selected as model in the present study. Western blot
analysis demonstrated the presence of a high molecular
weight band of expected size (Fig. 3a). Confocal micros-
copy showed the FAT1 distribution at the plasma mem-
brane of these cells (Fig. 3b-c). In addition, flow cytometry
analysis demonstrated both free mAb198.3_Cy5 and
AuCOOH(Cy5)_ mAb198.3 could bind to native FAT1
molecules on the surface of Colo205 cells (Fig. 3d-e). These
results indicated that mAb198.3 could be used as potential
target-specific delivery agents in vivo. Moreover, the mean
fluorescence intensity (MFI) of AuCOOH(Cy5)_ mAb198.3
is much higher than that of free mAb198.3_Cy5 (Fig. 3e).
This phenomenon was probably due to that Cy5 molecules
loaded on Au nanoparticles were much more than that on
mAb198.3.
Characterization of Au nanoparticles
The DLS size distribution profile of the AuCOOH,
AuCOOH(Cy5)_ mAb198.3, AuCOOH(Cy5)_ isotype
shows that the modified gold nanoparticles are well
dispersed in water, PBS buffer and cell culture medium
with 10 % FBS. Additional file 1: Figure S1A sum-
marizes the average particle size of AuCOOH,
AuCOOH(Cy5)_ mAb198.3, AuCOOH(Cy5)_ isotype.
The average particle size is about 12–24 nm with a narrow
size distribution. And the zeta potential was also deter-
mined and shown as −342.78 mV for AuCOOH(Cy5)_
mAb198.3 and −692.28 mV for AuCOOH(Cy5)_ isotype
in Additional file 1: Figure S1B. MAb usually increased
surface charge when conjugated to nanoparticles [32, 33]
and this generally results in increased tissue retention and
Fig. 2 a Western blot analysis of HeLa cells over-expressing FAT1 with mAb198.3. HeLa cells were transiently transfected with pcDNA3-FAT1
plasmid and the empty vector (Mock). At 48 h post transfection HeLa cell total lysates (25 micrograms/lane, corresponding to approximately
105 cells) were loaded onto SDS-PAGE, transferred to nitrocellulose membranes and probed with mAb198.3. Molecular weight standards
(MW) are reported on the left side. Arrow marks the expected protein size as determined from protein sequence. FAT1 detection in colon
adenocarcinoma tissues by IHC. In contrast to normal colon tissues b, expression of FAT1 was significantly upregulated in colon adenocarcinoma tissues
c-e. Bar, 50 μm. FAT1 detection in colon adenocarcinoma tissues by IHC. In contrast to non-adsorbed mAb198.3 f-g, the colon cancer tissue recognition
was abolished by adsorbing the antibody on the FAT1 recombinant domain, further demonstrating the specificity of the antibody recognition h-i
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increased blood clearance [34]. By TEM measurement,
the size of Au nanoparticles with spherical morphology is
about 10–20 nm (Additional file 1: Figure S1C).
Stability of AuCOOH_198.3 NPs in an acidic environ-
ment was investigated by incubating samples at varying pH
values for 4 h. A red shift in maximal absorbance wave-
length of the ultraviolet–visible (UV–vis) spectra in com-
parison to naked AuCOOH NPs (Δλmax > 10 nm) [35] was
regarded as evidence of aggregation. Figure 4 shows that
AuCOOH_198.3 NPs were found to aggregate below p
H 5.8. This was consistent with the visible change in
Fig. 5i-l, nanoparticles got aggregated inside endo-
lysosomes (pH < 5.8) and became scattered in cyto-
plasm after endo-lysosome escape.
Moreover, stability of AuCOOH_mAb198.3 NP in
PBS buffer, cell culture media and media with 10 %
serum was also investigated by the same method above.
No red-shift (Δλmax > 10 nm) is observed in three test-
ing groups, suggesting no aggregation appears when
AuCOOH_198.3 NPs dispersed in these three media
(Additional file 1: Figure S2). All of the data are re-
ported as the means ± S.D. Comparisons were carried
out with a one-way analysis of variance (ANOVA)
using GraphPad Prism 5.01 software. No significance
was found as P >0.05.
Cytotoxicity of Au nanoparticles
In this experiment, the toxicity of AuCOOH was studied
to confirm biocompatibility and evaluate the safety. We
quantified the toxicity of Au compounds in Colo205 cell
line by determining the IC50 values (Additional file 1:
Figure S3). Cytotoxic effects were not observed in Colo
205 cells treated with AuCOOH alone at the high
Fig. 3 Expression analysis of FAT1 in Colo205 cells. a Western blot analysis of total Colo205 extracts. Colo205 were lysed, separated on SDS-PAGE
(25 micrograms/lane, corresponding to approximately 105 cells), transferred to nitrocellulose membranes and incubated with mAb198.3. Molecular
weight standards (MW) are reported on the left side. b-c Confocal microscopy analysis: Cells were grown on glass coverslips, fixed and and incubated
with the mAb198.3. Cells were stained with Alexafluor 488-labeled goat anti-mouse antibodies to detect FAT1 (green) and DAPI to visualize nuclei (blue).
Flow cytometry analysis showing that both free mAb198.3_Cy5 d and AuCOOH(Cy5)_ mAb198.3 could bind Colo205 cells while the MFI of AuCOOH(Cy5)_
mAb198.3 is much higher than that of free mAb198.3_Cy5 e
Fig. 4 UV–vis spectra of AuCOOH_198.3 NPs at different pH values.
A red-shift (Δλmax > 10 nm) is observed as the pH is decreased from
6 to 5, suggesting aggregation
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concentration of 5 μM. The lack of significant growth
inhibition by the free AuCOOH NPs indicated that this
negative Au nanoparticles has well biocompatibility.
Intracellular uptake of Au nanoparticles
Our previous studies showed that mAb198.3 was effi-
ciently internalized in the Colo205 cell line when used
as naked antibody (Grifantini et al., submitted manu-
script). Next, we wished to confirm that mAb198.3 was
able to drive the intracellular delivery of AuCOOH nano-
particles in cancer cell lines. To this aim, we have per-
formed the intracellular uptake of AuCOOH_mAb198.3 in
Colo 205 cells at different culture time point by cell TEM,
as compared to AuCOOH, AuCOOH_ isotype as controls.
It could be seen obviously that in AuCOOH_mAb198.3
group (Fig. 5g-l), the intracellular gold amount was signifi-
cantly increased as culture time went by AuCOOH_-
mAb198.3 began to combine with the membrane microvilli
in the first 15 min (Fig. 5g) and followed by free diffusion
into the cells (Fig. 5h). In Fig. 5i-l, it could be observed very
clearly that Au nanoparticles can go through the cell mem-
brane into the cytoplasm and move towards cell nucleus
(Fig. 5k). The procedure of Au nanoparticles passing the
cell membrane through mAb198.3 mediated endocytosis
process was clearly observed in Fig. 5i. Part of the plasma
membrane was depressed to form small fossa, and fossa
further separated from the plasma membrane to form
coated vesicle. During this process, AuCOOH_mAb198.3
was brought into the cells. Plenty of Au nanoparticles was
observed in endocytic vesicles near the cell membrane and
in the cytoplasm (Fig. 5j and l), one step further confirming
the active targeting effect of mAb198.3. In contrast, during
the culture process within 4 h, AuCOOH(Cy5)_ isotype
(Fig. 5d-f) and bare AuCOOH (Fig. 5a-c) showed very low
uptake. Au nanoparticles were barely observed inside the
cell and no particles were found in the endocytic vesicles
(Fig. 5c). Glycogen granule (Gl), scattered in the cytoplasm,
has similar morphological characteristics with Au nanopar-
ticles except for larger size about 40 nm [36] in diameter. It
should be strictly distinguished from Au nanoparticles. Gl
can be easily identified after staining with lead, for instance.
Their diameter is slightly larger than that of the nearby
ribosomes (Ri) and averages 35 nm. The Gl usually occur
in clusters and stain intensely. Overall, our results indicate
that the conjugation of mAb198.3 on Au nanoparticles
might be again an effective delivery vehicle for negatively
Fig. 5 Transmission electron microscopy images of Au nanoparticles intracellular uptake by Colo 205 cells. After incubation with AuCOOH(a,15 min;
b,30 min; and c,4 h), AuCOOH(Cy5)_ isotype (negative control) (d,15 min; e,30 min; and f,4 h) and AuCOOH(Cy5)_ mAb198.3 (g,15 min; h,30 min; and
i-l,4 h), cells were collected and prepared for TEM analysis
Fan et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:103 Page 9 of 13
charged gold nanoparticles and its increased intracellular
transport.
Confocal microscopy was also used to monitor the
cellular uptake process. In Fig. 6a, it was clear that
mAb198.3 modified Au nanoparticles could attach to
the cell membrane in very short time (about 15 min)
through antigen antibody combination. After 30 min
incubation, AuCOOH(Cy5)_mAb198.3 was gradually
delivered into the cells. Cell membrane exhibited en-
hanced fluorescence intensity and fluorescence became
emerged in cytoplasm. After 4 h incubation, almost all
AuCOOH(Cy5)_mAb198.3 have been uptaken into or
surrounding the cytoplasm and nucleus so that the
cytoplasm presented bright red while the nucleus
turned purple (Mixed red and blue made the color
changed to purple). However, in the negative control
group, AuCOOH(Cy5)_ isotype rarely entered the cells
after 4 h incubation. The uptake efficiency increased
greatly with the modification of mAb198.3 onto the Au
nanoparticles surface. There could be two reasons for
this phenomenon. On one hand, considering the bio-
logical factors, we assume AuCOOH(Cy5)_ mAb198.3
might enter cells via receptor-mediated endocytosis
more efficiently than the AuCOOH(Cy5)_ isotype. Be-
sides, some non-biological factors are also crucial and
cannot be ignored such as particle size. Virtually, some
Fig. 6 a Confocal images of Colo 205 cells incubated with AuCOOH(Cy5)_ isotype (negative control) and AuCOOH(Cy5)_ mAb198.3 and nucleus
stained with DAPI. Incubated time: 15 min, 30,min and 4 h. (Blue fluorescence is associated with DAPI, and red fluorescence is associated with
Cy5). Scale bar at 20 μm. b Quantitative ICP-MS analysis of the number of AuCOOH, AuCOOH_isotype and AuCOOH_mAb198.3 in colo-205 cells.
All of the data are reported as the means ± S.D. Comparisons were performed with a one-way analysis of variance (ANOVA) followed by Bonferroni’s
multiple comparison tests using GraphPad Prism 5.01 software. Significance was defined as P < 0.0001 (***)
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larger and heavier particles such as AuCOOH(Cy5)_
mAb198.3 with average diameter of 24 nm can sediment
more quickly than those smaller ones (AuCOOH(Cy5)_
isotype with average diameter of 12 nm) and therefore
causing different dose of nanoparticles on the cell surface,
thus dramatically influencing the uptake extent.
Quantitative analysis of the number of AuCOOH,
AuCOOH_isotype and AuCOOH_mAb198.3 in colo-
205 cells was also determined by ICP-MS. In case of
AuCOOH_mAb198.3 (Fig. 6b), the intracellular gold
amount was significantly increased in colo-205 cells
compared to AuCOOH which showed very low uptake.
Therefore, attaching of mAb198.3 on AuCOOH surface
increased its intracellular transport. A similar uptake pro-
file was observed for AuCOOH_isotype and AuCO
OH_mAb198.3 in colo-205 cells, confirming that the pres-
ence of the isotype does not improve the uptake behavior
in colo-205 cells due to a lack of internalization function.
These results indicate that mAb198.3 can be an effective
delivery vehicle for negatively charged gold nanoparticles.
Therefore, from the above results of intracellular up-
take in vitro, AuCOOH(Cy5)_ mAb198.3 are nontoxic
to normal cells and could be potential target-specific
delivery agents.
Fig. 7 In vivo imaging of Colo 205 tumor bearing mice. Fluorescent signal captured by IVIS Lumina Imaging System in tumor bearing
mice after injection with AuCOOH(Cy5)_ mAb198.3 (a), AuCOOH(Cy5)_ isotype (b), and mAb198.3_Cy5 (c) for 24 h. Luminescent image
of resected organs from Colo 205 tumor-bearing mouse injected with AuCOOH(Cy5)_ mAb198.3 (d), AuCOOH(Cy5)_ isotype (e), and
mAb198.3_Cy5 (f) for 24 h
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In vivo bio-imaging study
In order to demonstrate the targeting efficiency of
AuCOOH(Cy5)_ mAb198.3 in vivo, bio-imaging study
was conducted using in vivo fluorescence imaging sys-
tem. Fluorescent images of treated mice were recorded
at 24 h post injection using an IVIS® Spectrum Imaging
System. As shown in Fig. 7a, intense fluorescence from
the tumor site can be clearly distinguished, due to
mAb198.3 guiding effect and EPR effect. On the con-
trary, weak fluorescence from the AuCOOH(Cy5)_ iso-
type treated cells can be detected 24 h post injection
(Fig. 7b). Still, some of AuCOOH(Cy5)_ isotype could
targeting delivery to tumor site due to EPR effect. Quan-
titative evaluation of the integrated fluorescence inten-
sity in tumor site (ROI, marked with blue circles of the
same size in Fig. 7) upon injection of AuCOOH(Cy5)_
mAb198.3, AuCOOH(Cy5)_ isotype, mAb198.3_Cy5 and
isotype_Cy5 were conducted using IVIS® Spectrum im-
aging software after substraction of auto fluorescence
(Fig. 7). The fluorescence intensity (4.294 × 1010) of
AuCOOH(Cy5)_ mAb198.3 treated group is ~9-fold
higher than that of AuCOOH(Cy5)_ isotype treated ones
(5.54 × 109) and ~5-fold higher than that of mAb198.3_Cy5
group (7.84 × 109) (Fig. 7c) upon 24 h post injection. In
order to further substantiate tumor-specific targeting from
passive accumulation of AuCOOH and provide sufficient
evidence for receptor-specific targeting of AuCOOH_-
mAb198.3, in-vivo quantification of NPs was determined
by ICP-MS analysis in three treatment groups (AuCOOH,
AuCOOH_isotype and AuCOOH_mAb198.3). Additional
file 1: Figure S4 shows that, only about 20 % of AuCOOH
accumulated at the tumor site due to the EPR effect, while
nearly 90 % of AuCOOH_mAb198.3 was found in the
tumor, providing sufficient evidence for receptor-specific
targeting by mAb198.3. To investigate the biodistribution
of AuCOOH(Cy5)_ mAb198.3, the mice were sacrificed
and the major organs and tumors were collected for im-
aging after intravenous injection of AuCOOH(Cy5)_
mAb198.3, AuCOOH(Cy5)_ isotype and mAb198.3_Cy5
for 24 h. Figure 7d-f show luminescent images of heart,
liver, spleen, lung, and kidney. As observed from the color
of Cy5, the Au nanoparticles are mainly accumulated in
the tumor, with some accumulation in the liver and kidney,
while there was no accumulation in the spleen and periph-
eral blood. The results revealed that weak fluorescence was
detected in the mouse tumors after 24 h of treatment with
AuCOOH(Cy5)_ isotyIntracellular negativepe and relative
stronger fluorescence mainly accumulated in the kidney
(Fig. 7e). Xenograft mice were likewise treated with
mAb198.3_Cy5 (Fig. 7f). Conjugation of Cy5 to mAb198.3
resulted in about a 15.5-fold increase in the delivery of
Cy5 to tumor tissue compared to the delivery of
AuCOOH(Cy5)_ isotype (ROI = 51.41). MAb198.3_Cy5
treatment resulted in a high level of fluorescence intensity
(ROI = 799.7) in the tumor and liver. However, treatment
with AuCOOH(Cy5)_ mAb198.3 resulted in highest level
of fluorescence intensity (ROI = 1465) in the tumor (about
28.4-fold compared with AuCOOH(Cy5)_ isotype treated
group) and a negligible intensity in the spleen and normal
liver tissue(Fig. 7d). In the AuCOOH(Cy5)_ isotype group
we observed a strong fluorescence intensity which accumu-
lated in liver and kidney while a weak fluorescence intensity
accumulated in the tumor. Overall, our results suggest that
mAb_198.3 has a strong targeting efficiency. It is worth
mentioning that in the AuCOOH(Cy5)_ mAb198.3 treated
group, an enhanced fluorescence could be detected in liver
metastases tissue. It also showed successful tumor delivery
of Au nanoparticles.
Conclusion
Herein, we demonstrated the use of a novel tumor tar-
geting antibody directed against colon expressed FAT1
(clone mAb198.3) used for intracellular negative gold
nanoparticles delivery. The size of mAb198.3 coated Au
nanoparticles with spherical morphology is about 20 nm
according to the DLS results with negative zeta poten-
tial. Our data further reveal that the system is stable
both in PBS and medium with serum. According to in
vitro cellular intracellular uptake and in vivo bio-
imaging studies, the intracellular uptake of negatively
charged AuCOOH_mAB198.3 particles is enhanced to a
greater extent. Thus, this system accumulation holds sig-
nificant potential to improve the treatment of cancer.
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